|
Age (years)
|
14
|
18
|
5
|
4
|
|
Gender
|
Male
|
Male
|
Male
|
Male
|
|
Clinical
|
Melena stools, fatigue
|
Leucocytosis, anaemia, thrombocytopenia no organomegaly
|
Generalized ecchymosis, bruises, epistaxis and hepatomegaly
|
Fever, malaise failure to thrive
|
|
WBC (109/L)
|
16.5
|
33
|
16.1
|
100
|
|
HB (g/dl)
|
10.1
|
8.2
|
6.7
|
7.8
|
|
PLT (X109/L)
|
20
|
67
|
14
|
101
|
|
PB blasts
|
30%
|
70%
|
40%
|
70%
|
|
Bone marrow aspirate
|
90% blasts with AML MO morphology
|
70% blasts
|
40% blasts With dysplasia
|
90% blasts comprised of two distinct populations
|
|
Blasts
|
90%
|
70%
|
40%
|
90%
|
|
Disease
|
AML MO
|
AML M2
|
AML M7
|
B/MYELOID
|
|
Cytogenetic analysis (karyotype/FISH)
|
46,XY,t(7;14) (q22;q32)
|
46,XY,t(11;20) (p15;q11), add(21)(p11)
|
t(12;17)(q15;q23), del(7)(p15), inv. (8)(q22q24) with(2+) and(19+)
|
46,XY,der(15)t(1;15) (q10;q10),der(17) t(17;19)(q21;p13.3)
|
|
Chemotherapy
|
Received induction (3 + 7) for AML then high risk MAC/G protocol
|
AML induction chemotherapy (3 + 7) protocol. Allogeneic stem cell transplant with steroid refractory graft vs host disease treated with ATG
|
MRC AML12 Protocol
|
Received 7 chemotherapy cycles
|
|
Survival
|
Refractory disease and demised secondary to chemotherapy side effects
|
Complete remission
|
Patient demised
|
Not attain remission Status. Relapsed for MUD transplant
|
